Last updated: April 26, 2026
Who Supplies Midazolam Hydrochloride Preservative-Free?
Midazolam hydrochloride preservative-free (PF) is supplied through a mix of branded specialty injectables, generic injectables, and sterile-compounding channels. Supplier lists below are organized by product type and manufacturer role (marketing authorization holder vs. sterile manufacturer vs. supplier of record where publicly disclosed).
What does “preservative-free” mean for midazolam injectable supply?
For midazolam hydrochloride injection, “preservative-free” generally refers to the absence of bacteriostatic preservatives (most commonly avoiding agents such as parabens or phenol) in the final sterile formulation. In practice, this drives sourcing toward:
- Single-dose vial presentations filled in sterile facilities with validated aseptic processing
- Or Hospital bulk/kit** supply chains where the end product is preservative-free by formulation and container closure system
Which manufacturers supply midazolam hydrochloride preservative-free injectable products?
Brand and authorization-holder suppliers
Public product catalogs and regulatory-facing listings typically show midazolam hydrochloride PF being marketed in injectable formats with vial sizes by the following groups:
- Hospira (Pfizer) legacy injectable supply (varies by market and listing status)
- B. Braun sterile injectable supply in multiple geographies
- Teva generic injectable supply in multiple geographies
- Fresenius Kabi sterile injectable supply in multiple geographies
- Sandoz generic injectable supply in multiple geographies
These firms are commonly present across injectable sterile portfolios and appear in multiple regulatory and procurement catalogs tied to midazolam injection SKUs. Product availability and PF labeling depend on the country-specific marketing listing for “preservative-free.”
How to treat “supplier” in procurement
Procurement lists often conflate three roles:
- Marketing Authorization Holder (MAH): legal supplier of record for the marketed product
- Manufacturer / sterile fill-finish site: physical production location
- Distributor: logistics and customer-facing supplier
For midazolam PF, the stable long-term sourcing decisions usually track MAH and fill-finish site, not the distributor.
What are the common dosing forms and SKU structures tied to PF supply?
Where do preservative-free presentations show up in supply chains?
Midazolam hydrochloride PF typically appears in:
- Injection for hospital use in single-dose vials
- Concentrations and vial sizes that align with anesthesia and procedural dosing workflows
Typical packaging patterns seen in procurement
Across countries where PF versions are listed, manufacturers usually offer:
- Single-unit sterile vials (often 1 mL and/or 2 mL presentations depending on market)
- Cartonized vial packs for operating-room inventory control
Supplier landscape by procurement model
Who supplies through commercial market procurement
Commercial procurement usually sources from:
- MAH-branded injectables
- Generic midazolam hydrochloride injectables with PF formulation and labeling
Common MAH-level players active across injectable sterile portfolios include:
- Pfizer/Hospira
- B. Braun
- Teva
- Fresenius Kabi
- Sandoz
Who supplies through tender and hospital group contracts
Hospital group tenders often award the PF midazolam SKU to whichever MAH-generic is currently supply-secure in that jurisdiction, with:
- Distributor networks changing frequently
- Manufacturer sites staying more consistent within a given MAH’s controlled supply chain
Regulatory-facing evidence used to identify true suppliers
How regulatory documents map to suppliers
When procurement requires “preservative-free,” suppliers must match:
- The registered product name including PF or equivalent formulation claim
- The sterile finished dosage form label
- The container closure system and dosing concentration for the exact SKU
Regulatory databases and EPAR/SmPC/labeling packages typically contain:
- MAH identity
- Manufacturer identity by site
- Composition and excipients (confirming absence of common preservatives)
Key supply risk factors for PF midazolam
PF injectables face procurement volatility driven by:
- Sterile fill-finish capacity constraints
- Aseptic processing lot-release bottlenecks
- Batch-specific sterility assurance and container closure inspection throughput
- Market-dependent PF formulation transitions (PF vs. multi-dose)
Key Takeaways
- Midazolam hydrochloride preservative-free injectable supply is dominated by large sterile injectable manufacturers and MAHs active in anesthesia and hospital portfolio dosing.
- Supplier identification should anchor to the exact registered PF-labeled SKU and its site-level manufacturer rather than distributor catalogs alone.
- Common MAH-level supplier groups active across geographies include Pfizer/Hospira, B. Braun, Teva, Fresenius Kabi, and Sandoz, but the PF designation is market- and SKU-specific.
FAQs
1) Is midazolam hydrochloride preservative-free always supplied as a single-dose vial?
In hospital markets, PF midazolam injection is most commonly packaged as single-dose vials to align with aseptic sterility expectations and dosing practices; some jurisdictions may vary by SKU.
2) Do distributors matter more than the MAH/manufacturer for PF compliance?
For compliance, the MAH and the registered sterile manufacturer site matter. Distributors change more often than the regulatory product.
3) Can a “midazolam injection” listing be PF even if the general brand is not?
Yes. PF labeling is SKU-specific and depends on the registered formulation and labeling in that jurisdiction.
4) What are the main drivers of PF midazolam supply interruptions?
Sterile fill-finish capacity, aseptic lot release and quality inspection throughput, and batch sterility assurance constraints.
5) How do procurement teams verify PF status quickly?
By matching the exact SKU to the registered product labeling that explicitly lists the preservative-free claim and by checking excipient composition in the product documentation.
References
[1] European Medicines Agency (EMA). Midazolam-containing medicinal products: EPAR and product information resources.
[2] U.S. Food and Drug Administration (FDA). Drug Approval Packages and labeling resources for midazolam hydrochloride injection products.
[3] World Health Organization (WHO). WHO Model Formulary and injectable guidance references for excipients and formulation considerations.
[4] EMA and national medicines agencies. SmPC/PL (product literature) data repositories for formulation and excipient verification.
